Exscientia Showcases Innovative Drug Development at ENA 2024
Exscientia plc (Nasdaq: EXAI), a pioneering technology-driven drug design company, is making waves at the 36th EORTC-NCI-AACR (ENA) Symposium 2024, being held from October 23-25. The company announced three significant abstracts focused on their cutting-edge AI-designed LSD1 and MALT1 inhibitors, demonstrating their commitment to advancing oncology treatments.
Exciting Advances in MALT1 Inhibition for B-cell Malignancies
One of the standout presentations, titled "Combining next-generation BTK and MALT1 inhibitors to enhance efficacy and therapeutic utility in B-cell malignancies," showcases the potential of EXS73565 (‘565), a potent and selective allosteric MALT1 inhibitor. Designed with a focus on an improved safety profile, clinical studies for ‘565 are expected to commence in early 2025, offering promising prospects for patients battling B-cell malignancies.
Potential Benefits of Combining Inhibitors
In collaboration with BTK inhibitors such as zanubrutinib, research has indicated that combining MALT1 inhibitors like ‘565 may enhance treatment efficacy. This combination provides greater inhibition of pathogenic nuclear factor-kappa B (NF-kB) signaling, which is pivotal in addressing drug resistance mechanisms. The experimental results demonstrate deeper and longer-lasting responses in xenograft models, particularly for activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL).
Confirmed Efficacy in Target Pathways
Interestingly, the studies confirmed that the effective pathways were engaged in the model systems. Both ‘565 and the combination with zanubrutinib have demonstrated the ability to inhibit NF-kB target gene expression, further establishing the framework for developing more potent B-cell malignancy treatments.
Innovations in LSD1 Inhibition for Acute Myeloid Leukemia (AML)
Another intriguing presentation at the symposium focuses on EXS74539, a novel and reversible LSD1 inhibitor demonstrating remarkable properties suitable for treating acute myeloid leukemia (AML). The poster describes how this innovative inhibitor is not only potent and selective but also designed with brain penetration in mind, which is critical for targeting central nervous system-related malignancies.
Identifying Pharmacodynamic Biomarkers
The findings highlighted in this study included identifying 12 potential pharmacodynamic (PD) biomarker gene candidates through ex vivo perturbation of primary human AML samples. These biomarkers correlate significantly with the activity of the LSD1 inhibitor. The upregulation of these gene candidates was subsequently confirmed in AML xenograft models post-treatment with ‘539, marking a step towards precision medicine.
Optimizing Treatment Side Effects
Furthermore, the treatment results indicate that ‘539 offers limited effects on platelet levels, a significant advantage that allows for maximizing target engagement while minimizing thrombocytopenia risks often associated with leukemia therapies.
Xcellomics and the Future of Drug Discovery
The final abstract sheds light on Xcellomics, a collaborative effort between Exscientia and The Centre for Medicines Discovery at the University of Oxford. This initiative aims to transform high-throughput screening (HTS) data into effective oncology therapeutics efficiently. The partnership has already made strides by identifying new essential regulators of a key oncogenic pathway.
Accelerating Drug Discovery
Exscientia's automated assay development has facilitated the rapid transition of these novel drug targets into viable discovery programs, showcasing a remarkable potential to change traditional drug development timelines significantly.
About Exscientia and its Vision for Drug Development
Exscientia remains at the forefront of AI-driven drug discovery, blending cutting-edge technology with a commitment to developing effective medicines faster than ever before. By emphasizing integrated experimentation and precision design, the company aims to reimagine the economics of drug creation, making strides in oncology and other therapeutic areas.
With a vision to bridge human expertise and technological innovation, Exscientia is poised to lead in the transformative landscape of drug discovery, advancing scientific ideas into viable medications for patients who need them most.
Frequently Asked Questions
What abstracts is Exscientia presenting at ENA 2024?
Exscientia is presenting three abstracts focused on their LSD1 and MALT1 inhibitors, including data on efficacy in B-cell malignancies and acute myeloid leukemia.
What are MALT1 inhibitors designed to do?
MALT1 inhibitors, such as EXS73565, are designed to enhance treatment effectiveness for B-cell malignancies by interfering with NF-kB signaling pathways.
When are the clinical studies for '565 expected to start?
Clinical studies for EXS73565 are anticipated to begin in early 2025.
How does EXS74539 target AML?
EXS74539 is a reversible LSD1 inhibitor that has been specifically designed to penetrate the brain and optimize treatment advantages against acute myeloid leukemia.
What is Xcellomics?
Xcellomics is a collaboration between Exscientia and the University of Oxford, designed to enhance drug discovery by applying advanced methodologies to translate screening results into oncology therapies.
